location_onIn Personopen_in_newExternal Event

MedTechConf Event

BioFIT 2026

Name: BioFIT 2026
Start: 2026-12-10T07:30:00+00:00
End: 2026-12-11T17:00:00+00:00
Location: Marseille, France

businessHosted by BioFIT

View Event Detailsopen_in_new

About This Event

BioFIT 2026 is the 15th edition of an international partnering event dedicated to technology transfer, academia-industry collaborations and early-stage investment in life sciences. The conference connects biotechnology and pharmaceutical companies, investors, researchers, technology transfer offices and emerging startups. Its program explores R&D partnerships, licensing strategies, investment opportunities, biotech entrepreneurship and animal health innovation through expert panels, practical sessions and partnering activities.

calendar_month

Date

Thursday, Dec 10, 2026–Friday, Dec 11, 2026

schedule

Time

08:30 AM

expand_more

location_city

Venue

Marseille

France

business

Hosted By

BioFIT

Speakers

AS
Adam Stoten
SVP Head of Academic Partnerships, Evotec
AD
Alberto Diaz Jimenez
Partnering Manager Search & Evaluation, Debiopharm
AG
Ana Gallego Roman
Business Development Manager, Vall d’Hebron Research Institute

location_on

Marseille, France | Rue Raymond Teisseire, Saint-Giniez, 8th Arrondissement, Marseille, Bouches-du-Rhône, Provence-Alpes-Côte d'Azur, Metropolitan France, 13008, France

mapLoading Map...

BioFIT 2026

View Event Details

Anela Vukoja

Partner, i&i Bio

Arezki Yaiche

Head of Coverage France & Benelux, Mergermarket (ION Group)

Benjamin Hall

Director and Head of the Circuit Biology Department, Lundbeck

Claudia Andretta

Strategic Advisor

David Findlay

CEO, Rostra Therapeutics

Fábio Rosa

Co-founder and Head of Research, Asgard Therapeutics

Fabrizio Conicella

Vice President, Center of Open Innovation & Competence, Chiesi

Farzad Abdi-Dezfuli

Partner, Sarsia

Florence De Coorebyter

Associate, Kurma Partners

Gerald Law

Chief Executive, Innovation DB

Gilles Brackman

Senior Business Developer Medical Technologies, Ghent University

Guerric Radière

Founding Partner, Lamina Partners

Hanno Ronte

Partner, Deloitte

Ingrid Kelly Spillmann

Partner, Xista Science Ventures

Jan-Philipp Kruse

Senior Director, Lilly Ventures

Joana Caldeira

CEO, Fetalix

Julie Prasivoravong

CMO, STEOM

Karin Agerman

Senior Business Advisor, Karolinska Institutet Innovation

Laura Donnelly

Associate Commercialisation Director, Cambridge Enterprise

Lilian Alcaraz

Director, AlcaBridge Bio Consulting

Oliver Boucher

Vice President, Business Development & Strategic Alliances, Zoetis

Pedro Lopes

Head of IP and Tech Transfer, CeMM

Pierre Gaudeaux

Associate Director of Investments, Sanofi

Poul Sørensen

CEO, Inverna Therapeutics

Prabhu Velusami

Senior Director Search and Evaluation, External Scientific Innovation, Johnson & Johnson

Ramsay McFarlane

CEO, Awen Oncology

Raoul Haschke

Head of Hei Innovation, Heidelberg University

Ricardo Pacheco

Strategic Partnering BD&L Director, Insilico Medicine

Rudi Pauwels

Pharmaceutical Scientist, Virologist, Biotech Entrepreneur, Tibotec, Virco, Biocartis, ANeuroTech & Praesens Foundation

Savita Bernal

Director Acceleration of Innovation and Entrepreneurship, Inserm Transfert

Teresa De Nadai

Project Manager, LIFTT

Ulrich Wendt

Chief Business Officer, Alchemab Therapeutics

Wim van der Poel

Professor of Emerging and Zoonotic Viruses, Wageningen University

Yanis Feraoun

Investment Manager, Andera Partners

Program

All times are in Europe/Paris.

Day 1Thursday, 10 December 2026

10:00 – 11:00
Investment under the microscope: 2026 review and how capital will be allocated in 2027
location_onIn person
Panel discussion reviewing early-stage life sciences investment trends in 2026 and exploring how investors may allocate capital in 2027.
- HRHanno Ronte
11:30 – 12:30
From scientific excellence to competitive innovation: How Europe is strengthening its life sciences translation power
location_onIn person
Plenary discussion examining how Europe can strengthen technology transfer, commercialization and competitiveness in global life sciences innovation.
- RHRaoul Haschke
- GLGerald Law
- FCFabrizio Conicella
- SBSavita Bernal
- YFYanis Feraoun
14:00 – 14:45
Collaborative models accelerating One Health innovation: The case of emerging infectious diseases
location_onIn person
Panel examining technology transfer, partnerships and collaboration models that accelerate innovation addressing emerging infectious diseases.
- GRGuerric Radière
- OBOliver Boucher
- WVWim van der Poel
16:15 – 17:00
It's never too early for TPP: Best practices for young founders
location_onIn person
Practical session explaining how early-stage founders can develop and refine target product profiles to guide product development and commercialization.
- FAFarzad Abdi-Dezfuli
- RPRicardo Pacheco
- GBGilles Brackman
- IKIngrid Kelly Spillmann
17:15 – 18:00
Fewer seed rounds and alternative financing strategies: They chose to collaborate with patient associations
location_onIn person
Case studies exploring collaborations with patient associations as an alternative financing and development strategy for early-stage biotechnology companies.
- PSPoul Sørensen
- AVAnela Vukoja

Day 2Friday, 11 December 2026

09:15 – 10:00
Taking the collaboration to the next level: What triggers Pharma to bring equity in biotech companies?
location_onIn person
Discussion examining the factors influencing pharmaceutical companies to invest equity in biotechnology partners and the implications of these investment decisions.
- LALilian Alcaraz
- PGPierre Gaudeaux
- UWUlrich Wendt
- JKJan-Philipp Kruse

What makes an academic asset collaboration-ready for Pharma nowadays?

location_onIn person

Panel exploring the scientific evidence, commercial readiness, development plans and organizational capabilities that pharmaceutical companies evaluate before entering academic partnerships.

AGAna Gallego Roman
CAClaudia Andretta
KAKarin Agerman
ADAlberto Diaz Jimenez

11:30 – 12:30

From academia to industry: Scientists turned CEOs share their experience of entrepreneurship

location_onIn person

Biotechnology founders discuss their transition from academic research into company leadership and share lessons from building science-based businesses.

GLGerald Law
JCJoana Caldeira
RMRamsay McFarlane
JPJulie Prasivoravong
FRFábio Rosa

14:15 – 15:00

Too early for VC: best practices in building the bridge towards Series A

location_onIn person

Practical discussion examining funding gaps between early research and Series A investment, including alternative capital sources and investor expectations.

CAClaudia Andretta
LDLaura Donnelly
TDTeresa De Nadai

15:30 – 16:15

How TTOs and venture builders collaborate to create more attractive start-ups

location_onIn person

Panel examining collaboration between technology transfer offices and venture builders to support academic spinouts, accelerate commercialization and attract investment.

ASAdam Stoten
AYArezki Yaiche
FDFlorence De Coorebyter
PLPedro Lopes

BioFIT 2026

About This Event

Speakers

BioFIT 2026

Program

Day 1Thursday, 10 December 2026

Investment under the microscope: 2026 review and how capital will be allocated in 2027

From scientific excellence to competitive innovation: How Europe is strengthening its life sciences translation power

Collaborative models accelerating One Health innovation: The case of emerging infectious diseases

It's never too early for TPP: Best practices for young founders

Fewer seed rounds and alternative financing strategies: They chose to collaborate with patient associations

Day 2Friday, 11 December 2026

Taking the collaboration to the next level: What triggers Pharma to bring equity in biotech companies?

Similar Events

Trinational HealthTech Days 2026

MedFIT 2026

Global Pharma and Biotech Summit 2026

ICR Healthcare's 14th Annual Healthcare Conference

What makes an academic asset collaboration-ready for Pharma nowadays?

From academia to industry: Scientists turned CEOs share their experience of entrepreneurship

Too early for VC: best practices in building the bridge towards Series A

How TTOs and venture builders collaborate to create more attractive start-ups